JET2024 will be held in Fukuoka for the first time in 8 years. The conference will take place at the Fukuoka International Congress Center for 3 days from June 14th (Fri) to 16th (Sun), 2024. Eight years ago, the JET conference was held at the Hilton Fukuoka Sea Hawk. The program was prepared together with Dr. Tatsuya Nakama and Dr. Masahiko Fujihara, who were in their late thirties, and we included more English sessions than before and gathered many participants from overseas, making it a great turning point for JET—it swung its focus from within Japan to the world, and program preparation was entrusted to young physicians of the next generation. Located near other Asian countries, Fukuoka has the potential for international development, with an atmosphere that encourages challenges without fear of failure and learning from failures for future improvement. We believe these characteristics of the city played a part in achieving our turning point.
In the 8 years since then, the situation surrounding healthcare has changed considerably. In particular, the COVID-19 outbreak that started in 2020 has had enormous impacts, requiring cancellations and delays of society activities such as conferences, seminars/workshops, and live demonstrations that have significantly contributed to the evolution and spread of endovascular intervention. Despite these circumstances, JET has continued to tackle challenges and has not stopped its advancement. JET2020 became the first academic conference to be held remotely in Japan, and JET2021 and JET2022 were held as hybrid meetings mixing remote and on-site participation. Dr. Osamu Iida and Dr. Fujihara’s considerable efforts over these 3 years in Osaka have significantly contributed to the advancement of JET. JET2023 was held in Tokyo entirely on-site. Under the supervision of Dr. Masato Nakamura (Chairman), an excellent program for JET2023 was created by Dr. Nakama, Dr. Makoto Utsunomiya, and Dr. Kenji Suzuki, who are the main members of the Tokyo Endovascular Challenging Conference (TECC), a consortium that grew during the COVID-19 outbreak. JET2023 was a success and gathered the largest number of participants ever from Japan and overseas.
JET has grown because of the enthusiasm of clinical physicians for curing currently incurable diseases in the future. JET has observed and intervened in diseases from a vantage point closest to patients and has continued to innovate consistently to fulfill its philosophy. The innovation that JET seeks is to achieve novel collaborations by various methods, which requires passionate face-to-face interdisciplinary discussions among physicians, companies, and the government beyond the borders of countries. Guidelines can be disseminated remotely, but new evidence supporting changes to guidelines cannot be generated without face-to-face interaction. JET2024 will also be held completely on-site, so we are looking forward to seeing many participants in Fukuoka in the early summer.
The theme of JET2024 is “Sustainable Development Goals (SDGs) for Endovascular Treatment”. This is a new development goal to achieve and sustain further advancements in this field, which has evolved over the past 20 years. In addition to existing themes (PAD, CLTI, Aorta, Shunt, and Venous), we will add RDN, Stroke, ALI, and PE as new session themes. We hope that participants will have in-depth discussions and learn via the live demonstrations, lectures, debates, and THM.
We have prepared the JET2024 program with the hope of passing on the endovascular intervention legacy to the next generation and helping young physicians be ambitious and realize their dreams. We look forward to your participation in JET2024 in Fukuoka.
To be involved in medicine, you must innovate.
President, JET2024
Hiroyoshi Yokoi, MD
Fukuoka Sanno Hospital/International University of Health and Welfare
